Opevesostat

Opevesostat

Clinical data
Other names	MK-5684, ODM-208
Identifiers
IUPAC name 2-(1,3-dihydroisoindol-2-ylmethyl)-5-[(1-methylsulfonylpiperidin-4-yl)methoxy]pyran-4-one
CAS Number	2231294-96-3
PubChem CID	135151902
ChemSpider	128942316
UNII	1Z7MAV4KQC
ChEMBL	ChEMBL5314533
Chemical and physical data
Formula	C21H26N2O5S
Molar mass	418.51 g·mol−1
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)N1CCC(CC1)COC2=COC(=CC2=O)CN3CC4=CC=CC=C4C3
InChI InChI=InChI=1S/C21H26N2O5S/c1-29(25,26)23-8-6-16(7-9-23)14-28-21-15-27-19(10-20(21)24)13-22-11-17-4-2-3-5-18(17)12-22/h2-5,10,15-16H,6-9,11-14H2,1H3 Key:LHVKCOBGLZGRQZ-UHFFFAOYSA-N

Opevesostat is an investigational new drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a non-steroidal, selective inhibitor of CYP11A1 (cholesterol side-chain cleavage enzyme) discovered by Orion Corporation and currently undergoing clinical development by Merck & Co., Inc. Opevesostat's mechanism of action involves suppressing the production of steroid hormones and their precursors that may activate the androgen receptor signaling pathway, which is crucial in prostate cancer progression. As of 2024, opevesostat is being evaluated in two Phase 3 clinical trials, OMAHA1 and OMAHA2a, which are assessing its efficacy and safety in combination with hormone replacement therapy for patients with mCRPC who have failed prior treatments.